NASDAQ:CPRX Stock Quote
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases
The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas.
Frequently Asked Questions
Does Catalyst Pharmaceuticals focus on other rare diseases?
While Catalyst Pharmaceuticals primarily centers on rare neurological diseases, the company explores the potential of its formulations in other rare and underserved medical conditions, thereby broadening its therapeutic focus and impact on public health.
Does Catalyst Pharmaceuticals have any ongoing clinical trials?
Yes, Catalyst Pharmaceuticals is actively conducting clinical trials as part of its commitment to developing new therapies. The company often engages in trials for new indications of its existing products and for novel compounds that may enter its pipeline.
How can investors learn more about Catalyst Pharmaceuticals?
Investors can find detailed information about Catalyst Pharmaceuticals, including financial reports, corporate announcements, and stock performance, on its official website and through regulatory filings available on the SEC website. Additionally, the company regularly schedules investor conference calls and presentations.
How does Catalyst Pharmaceuticals approach patient advocacy?
Catalyst Pharmaceuticals is dedicated to working closely with patient advocacy groups to understand the needs and challenges faced by patients with rare neurological diseases. The company believes in fostering partnerships to ensure that the voices of patients are heard in the development process.
How does Catalyst Pharmaceuticals maintain its competitive edge?
Catalyst Pharmaceuticals maintains its competitive edge through innovation, dedicated research efforts, and strategic partnerships that enhance product development. The company continuously invests in understanding the needs of its target patient populations and staying ahead in the rapidly evolving biopharmaceutical landscape.
How does Firdapse work?
Firdapse works by increasing the release of acetylcholine at the neuromuscular junction, thereby enhancing muscle contractions and improving muscle strength. This mechanism is particularly beneficial for patients with LEMS, where the transmission of nerve signals is disrupted.
Is Firdapse an approved medication?
Yes, Firdapse (amifampridine) is an FDA-approved medication specifically indicated for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). The approval of Firdapse marked a significant advancement in available therapies for patients with this condition.
What are the future plans for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals plans to expand its product pipeline by continuing research into additional rare neurological disorders and developing therapeutic options for these conditions. The company aims to leverage its expertise to enhance patient outcomes and fulfill unmet medical needs.
What challenges does Catalyst Pharmaceuticals face?
Catalyst Pharmaceuticals faces challenges typical of the biopharmaceutical sector, including stringent regulatory requirements, the high cost of drug development, and competition from other companies. The company navigates these challenges through strategic planning, robust clinical trials, and building strong relationships with key stakeholders.
What does Catalyst Pharmaceuticals, Inc. do?
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of rare neurological diseases. The company primarily targets disorders such as Lambert-Eaton Myasthenic Syndrome (LEMS) and other conditions characterized by muscle weakness and neurological impairment.
What impact has Firdapse had on patients with LEMS?
Firdapse has had a significant positive impact on patients with Lambert-Eaton Myasthenic Syndrome (LEMS) by improving muscle strength and, consequently, the overall quality of life. Patients have reported notable improvements in daily activities and their ability to engage socially post-treatment.
What is the company’s approach to regulatory compliance?
Catalyst Pharmaceuticals adheres to stringent regulatory requirements set by the U.S. FDA and other health authorities. The company is committed to maintaining high standards of quality and compliance throughout its research, development, and commercial activities to ensure the safety of its products.
What is the mission of Catalyst Pharmaceuticals?
The mission of Catalyst Pharmaceuticals is to develop and provide innovative therapies that improve the lives of patients suffering from rare neurological diseases. The company is committed to addressing unmet medical needs and advancing research in this specialized field.
What is the primary product of Catalyst Pharmaceuticals?
The primary product of Catalyst Pharmaceuticals is Firdapse (amifampridine), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of LEMS. Firdapse serves as a critical therapeutic option for patients suffering from this rare autoimmune disorder.
What is the significance of the Nasdaq listing for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals is listed on the Nasdaq stock exchange under the ticker symbol CPRX. Being publicly traded on Nasdaq provides the company with access to capital markets to fund research and development initiatives and enhance visibility among investors.
When was Catalyst Pharmaceuticals founded?
Catalyst Pharmaceuticals was founded in 2002. Since its inception, the company has been dedicated to the discovery and development of treatments aimed at addressing unmet medical needs in the field of rare diseases.
Where is Catalyst Pharmaceuticals located?
Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida. Its location provides the company with access to a vibrant biopharmaceutical community and proximity to research institutions and healthcare resources.
Who are the key executives at Catalyst Pharmaceuticals?
The key executives at Catalyst Pharmaceuticals include Chief Executive Officer (CEO) Patrick J. McEnany and other senior leadership team members with extensive experience in biotechnology and pharmaceuticals. This seasoned team drives the company's strategic direction and operational execution.
What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?
The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 24.43
When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 2:24 pm EDT on April 2nd, 2025
What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 2.51B
How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?
Catalyst Pharmaceuticals, Inc. - Common Stock has 102.78M shares outstanding.